Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA; Cancer and Leukemia Group B Experience. Muss HB, et al. Among authors: budman dr. J Clin Oncol. 2007 Aug 20;25(24):3699-704. doi: 10.1200/JCO.2007.10.9710. J Clin Oncol. 2007. PMID: 17704418 Clinical Trial.
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, Henderson IC, Norton L, Hayes DF. Guidi AJ, et al. Among authors: budman dr. J Clin Oncol. 2002 Feb 1;20(3):732-42. doi: 10.1200/JCO.2002.20.3.732. J Clin Oncol. 2002. PMID: 11821455 Clinical Trial.
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. DiGiovanna MP, et al. Among authors: budman dr. J Clin Oncol. 2008 May 10;26(14):2364-72. doi: 10.1200/JCO.2007.13.6580. Epub 2008 Apr 7. J Clin Oncol. 2008. PMID: 18390970 Free PMC article. Clinical Trial.
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS; Cancer and Leukemia Group B 89803. Meyerhardt JA, et al. J Clin Oncol. 2008 Sep 1;26(25):4109-15. doi: 10.1200/JCO.2007.15.6687. J Clin Oncol. 2008. PMID: 18757324 Free PMC article. Clinical Trial.
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J, Cirrincione C, Perloff M, Perry M, Budman D, Abrams J, Panasci L, Muss H, Citron M, Holland J, et al. Aisner J, et al. J Clin Oncol. 1995 Jun;13(6):1443-52. doi: 10.1200/JCO.1995.13.6.1443. J Clin Oncol. 1995. PMID: 7751891 Clinical Trial.
198 results